Andre Strydom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3593897/publications.pdf

Version: 2024-02-01

153 papers 6,734 citations

45 h-index 79698 73 g-index

192 all docs

192 docs citations

192 times ranked 5683 citing authors

#	Article	IF	CITATIONS
1	A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nature Reviews Neuroscience, 2015, 16, 564-574.	10.2	404
2	Down syndrome. Nature Reviews Disease Primers, 2020, 6, 9.	30.5	376
3	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.8	310
4	Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ, The, 2015, 351, h4326.	6.0	244
5	Self stigma in people with intellectual disabilities and courtesy stigma in family carers: A systematic review. Research in Developmental Disabilities, 2012, 33, 2122-2140.	2.2	237
6	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
7	Discrimination and Other Barriers to Accessing Health Care: Perspectives of Patients with Mild and Moderate Intellectual Disability and Their Carers. PLoS ONE, 2013, 8, e70855.	2.5	203
8	Behavioural and psychological symptoms ofÂdementia in Down syndrome: Early indicators ofÂclinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	2.4	201
9	Major Health Risks in Aging Persons With Intellectual Disabilities: An Overview of Recent Studies. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 59-69.	2.7	165
10	The importance of understanding individual differences in Down syndrome. F1000Research, 2016, 5, 389.	1.6	151
11	Prevalence of dementia in intellectual disability using different diagnostic criteria. British Journal of Psychiatry, 2007, 191, 150-157.	2.8	134
12	Long-term affective disorder in people with mild learning disability. British Journal of Psychiatry, 2001, 179, 523-527.	2.8	110
13	Dementia in Older Adults With Intellectual Disabilities-Epidemiology, Presentation, and Diagnosis. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 96-110.	2.7	110
14	Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology, 2019, 76, 152.	9.0	110
15	Incidence of dementia in older adults with intellectual disabilities. Research in Developmental Disabilities, 2013, 34, 1881-1885.	2.2	105
16	Psychiatric morbidity and social functioning among adults with borderline intelligence living in private households. Journal of Intellectual Disability Research, 2008, 52, 95-106.	2.0	100
17	Trisomy of human chromosome 21 enhances amyloid- \hat{l}^2 deposition independently of an extra copy of <i> APP < /i>. Brain, 2018, 141, 2457-2474.</i>	7.6	96
18	Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 717-728.	2.6	94

#	Article	IF	CITATIONS
19	Aging in Down Syndrome: Morbidity and Mortality. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 70-81.	2.7	85
20	Health comorbidities and cognitive abilities across the lifespan in Down syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 4.	3.1	85
21	The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of ID. Psychological Medicine, 2009, 39, 13-21.	4.5	78
22	Dementia diagnostic criteria in Down syndrome. International Journal of Geriatric Psychiatry, 2015, 30, 857-863.	2.7	77
23	Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021, 33, 100769.	7.1	73
24	Diagnostic instruments for dementia in older people with intellectual disability in clinical practice. Aging and Mental Health, 2003, 7, 431-437.	2.8	71
25	Older adults with intellectual disability. Current Opinion in Psychiatry, 2012, 25, 359-364.	6.3	68
26	Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257.	0.8	68
27	Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 741-751.	3.7	64
28	Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open, 2017, 7, e017406.	1.9	63
29	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	3.7	63
30	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	7.9	63
31	Psychiatric morbidity in prisoners with intellectual disabilities: analysis of prison survey data for England and Wales. British Journal of Psychiatry, 2011, 199, 156-157.	2.8	62
32	Clinical outcomes of staff training in positive behaviour support to reduce challenging behaviour in adults with intellectual disability: cluster randomised controlled trial. British Journal of Psychiatry, 2018, 212, 161-168.	2.8	61
33	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 3-9.	2.9	61
34	Manualised Individual Cognitive Behavioural Therapy for mood disorders in people with mild to moderate intellectual disability: A feasibility randomised controlled trial. Journal of Affective Disorders, 2013, 151, 186-195.	4.1	59
35	Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiatry, the, 2014, 1, 522-530.	7.4	58
36	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 26.	6.2	56

#	Article	IF	CITATIONS
37	Social outcomes in adulthood of children with intellectual impairment: evidence from a birth cohort. Journal of Intellectual Disability Research, 2005, 49, 171-182.	2.0	55
38	The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Research, 2016, $1,11.$	1.8	55
39	Self-reported stigma and symptoms of anxiety and depression in people with intellectual disabilities: Findings from a cross sectional study in England. Journal of Affective Disorders, 2015, 187, 224-231.	4.1	54
40	Cognitive decline and dementia in Down syndrome. Current Opinion in Psychiatry, 2017, 30, 102-107.	6.3	54
41	Oxidative stress and cognitive ability in adults with Down syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 76-80.	4.8	52
42	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.8	52
43	A measure of perceived stigma in people with intellectual disability. British Journal of Psychiatry, 2008, 193, 410-415.	2.8	51
44	Service use and cost of mental disorder in older adults with intellectual disability. British Journal of Psychiatry, 2010, 196, 133-138.	2.8	48
45	The relationship between happiness and intelligent quotient: the contribution of socio-economic and clinical factors. Psychological Medicine, 2013, 43, 1303-1312.	4.5	47
46	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. Acta Neuropathologica, 2018, 136, 569-587.	7.7	47
47	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer's Research and Therapy, 2018, 10, 39.	6.2	43
48	Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study. Journal of Alzheimer's Disease, 2012, 31, 277-283.	2.6	42
49	Clinical use of structural magnetic resonance imaging in the diagnosis of dementia in adults with Down's syndrome. Irish Journal of Psychological Medicine, 2002, 19, 60-63.	1.0	41
50	Mental Health and Social Care Needs of Older People with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2005, 18, 229-235.	2.0	40
51	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease, 2018, 63, 797-819.	2.6	38
52	Clinical and cost effectiveness of staff training in Positive Behaviour Support (PBS) for treating challenging behaviour in adults with intellectual disability: a cluster randomised controlled trial. BMC Psychiatry, 2014, 14, 219.	2.6	36
53	Cognitive behaviour therapy (CBT) for anxiety and depression in adults with mild intellectual disabilities (ID): a pilot randomised controlled trial. Trials, 2011, 12, 95.	1.6	33
54	Assessing Specific Cognitive Deficits Associated with Dementia in Older Adults with Down Syndrome: Use and Validity of the Arizona Cognitive Test Battery (ACTB). PLoS ONE, 2016, 11, e0153917.	2.5	33

#	Article	lF	CITATIONS
55	Standardised patients with intellectual disabilities in training tomorrow's doctors. Psychiatric Bulletin (2014), 2014, 38, 132-136.	0.3	32
56	Use of medication for challenging behaviour in people with intellectual disability. British Journal of Psychiatry, 2014, 205, 6-7.	2.8	30
57	Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability. Drugs and Aging, 2015, 32, 95-102.	2.7	30
58	Intracerebral haemorrhage in Down syndrome: protected or predisposed?. F1000Research, 2016, 5, 876.	1.6	30
59	Self-reported stigma and its association with socio-demographic factors and physical disability in people with intellectual disabilities: results from a cross-sectional study in England. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 465-474.	3.1	30
60	Chromosomal microarray testing in adults with intellectual disability presenting with comorbid psychiatric disorders. European Journal of Human Genetics, 2017, 25, 66-72.	2.8	30
61	Neurodevelopmental risk copy number variants in adults with intellectual disabilities and comorbid psychiatric disorders. British Journal of Psychiatry, 2018, 212, 287-294.	2.8	30
62	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NeuroMolecular Medicine, 2021, 23, 561-571.	3.4	30
63	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
64	Understanding inequalities in COVID-19 outcomes following hospital admission for people with intellectual disability compared to the general population: a matched cohort study in the UK. BMJ Open, 2021, 11, e052482.	1.9	29
65	Caregiving and Adults With Intellectual Disabilities Affected by Dementia. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 26-33.	2.7	28
66	Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. British Journal of Psychiatry, 2018, 212, 155-160.	2.8	28
67	Does rare matter? Copy number variants at 16p11.2 and the risk of psychosis: A systematic review of literature and meta-analysis. Schizophrenia Research, 2014, 159, 340-346.	2.0	27
68	Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS). PLoS ONE, 2016, 11, e0154596.	2.5	27
69	Carer-led health interventions to monitor, promote and improve the health of adults with intellectual disabilities in the community: A systematic review. Research in Developmental Disabilities, 2014, 35, 887-907.	2.2	26
70	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. Journal of Neurodevelopmental Disorders, 2019, 11, 20.	3.1	26
71	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. Frontiers in Immunology, 2021, 12, 621440.	4.8	26
72	Randomized trial of psychotropic medication information leaflets for people with intellectual disability. Journal of Intellectual Disability Research, 2001, 45, 146-151.	2.0	24

#	Article	IF	CITATIONS
73	A memory clinic for older people with intellectual disabilities. Aging and Mental Health, 2003, 7, 418-423.	2.8	24
74	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	2.4	24
75	Patient information leaflets for people with learning disabilities who take psychiatric medication. British Journal of Learning Disabilities, 2001, 29, 72-76.	1.1	23
76	From <i>DSM</i> to <i>DM-ID</i> . Journal of Mental Health Research in Intellectual Disabilities, 2016, 9, 189-204.	2.0	23
77	Assessing Autism in Adults: An Evaluation of the Developmental, Dimensional and Diagnostic Interview—Adult Version (3Di-Adult). Journal of Autism and Developmental Disorders, 2018, 48, 549-560.	2.7	21
78	Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity. Neuroscience Letters, 2017, 636, 254-257.	2.1	20
79	Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability. PLoS ONE, 2019, 14, e0221507.	2.5	20
80	Dynamic Causal Modeling of the Relationship between Cognition and Theta–alpha Oscillations in Adults with Down Syndrome. Cerebral Cortex, 2019, 29, 2279-2290.	2.9	20
81	Dynamics of plasma biomarkers in Down syndrome: the relative levels of $A\hat{l}^2$ 42 decrease with age, whereas NT1 tau and NfL increase. Alzheimer's Research and Therapy, 2020, 12, 27.	6.2	20
82	Positive behaviour support training for staff for treating challenging behaviour in people with intellectual disabilities: a cluster RCT. Health Technology Assessment, 2018, 22, 1-110.	2.8	20
83	What to tell and how to tell: a qualitative study of information sharing in research for adults with intellectual disability. Journal of Medical Ethics, 2008, 34, 501-506.	1.8	19
84	Validity of Criteria for Dementia in Older People With Intellectual Disability. American Journal of Geriatric Psychiatry, 2013, 21, 279-288.	1.2	19
85	Psychotropic prescribing in people with intellectual disability and challenging behaviour. BMJ: British Medical Journal, 2017, 358, j3896.	2.3	19
86	Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing. JAMA Network Open, 2018, 1, e183750.	5.9	19
87	Evaluation of medical students' attitudes towards people with intellectual disabilities: a naturalistic study in one medical school. Advances in Mental Health and Intellectual Disabilities, 2013, 7, 18-26.	1.1	18
88	Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. Aging and Mental Health, 2018, 22, 1406-1415.	2.8	18
89	Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and metaâ€analyses. Developmental Neurobiology, 2019, 79, 684-698.	3.0	18
90	Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome. Frontiers in Psychiatry, 2019, 10, 158.	2.6	18

#	Article	IF	CITATIONS
91	Reliance on Carer Reports of Early Symptoms of Dementia Among Adults With Intellectual Disabilities. Journal of Policy and Practice in Intellectual Disabilities, 2010, 7, 34-41.	2.7	17
92	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. PLoS ONE, 2014, 9, e97709.	2.5	17
93	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3639.	2.4	17
94	Ethnicity and selfâ€reported experiences of stigma in adults with intellectual disability in <scp>C</scp> ape <scp>T</scp> own, <scp>S</scp> outh <scp>A</scp> frica. Journal of Intellectual Disability Research, 2015, 59, 530-540.	2.0	16
95	Delineating the psychiatric and behavioral phenotype of recurrent 2q13 deletions and duplications. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 397-405.	1.7	16
96	Genetic testing in intellectual disability psychiatry: Opinions and practices of <scp>UK</scp> child and intellectual disability psychiatrists. Journal of Applied Research in Intellectual Disabilities, 2018, 31, 273-284.	2.0	16
97	Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. Alzheimer's and Dementia, 2021, 17, 595-604.	0.8	16
98	Estimated verbal IQ and the odds of problem gambling: a population-based study. Psychological Medicine, 2014, 44, 1739-1749.	4.5	15
99	Use of the HoNOS–LD in identifying domains of change. The Psychiatrist, 2010, 34, 322-326.	0.3	14
100	Crossâ€Cultural Validation of a Measure of Felt Stigma in People with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2012, 25, 11-19.	2.0	14
101	Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open, 2019, 9, e032861.	1.9	14
102	The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 1882.	2.4	14
103	Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Journal of Neurodevelopmental Disorders, 2022, 14, 22.	3.1	13
104	Intellectual disability across cultures. Psychiatry (Abingdon, England), 2009, 8, 355-357.	0.2	12
105	Prisoners with intellectual disabilities and detention status. Findings from a UK cross sectional study of prisons. Research in Developmental Disabilities, 2016, 53-54, 189-197.	2.2	12
106	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12062.	2.4	12
107	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 350-356.	2.0	11
108	Genetic dissection of down syndrome-associated alterations in APP/amyloid- \hat{l}^2 biology using mouse models. Scientific Reports, 2021, 11, 5736.	3.3	10

#	Article	IF	CITATIONS
109	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12184.	2.4	10
110	Clinical and cost effectiveness of staff training in the delivery of Positive Behaviour Support (PBS) for adults with intellectual disabilities, autism spectrum disorder and challenging behaviour - randomised trial. BMC Psychiatry, 2020, 20, 161.	2.6	9
111	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. Journal of Clinical Medicine, 2021, 10, 4582.	2.4	9
112	Diagnosis of Attention Deficit Hyperactivity Disorder in Intellectual Disability: Diagnostic and Statistical Manual of Mental Disorder V versus clinical impression. Journal of Intellectual Disability Research, 2020, 64, 251-257.	2.0	8
113	Comparison of resting-state EEG between adults with Down syndrome and typically developing controls. Journal of Neurodevelopmental Disorders, 2021, 13, 48.	3.1	8
114	COVID-19 Vaccination of Individuals with Down Syndromeâ€"Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	4.4	8
115	Susceptibility to COVID-19 Diagnosis in People with Down Syndrome Compared to the General Population: Matched-Cohort Study Using Primary Care Electronic Records in the UK. Journal of General Internal Medicine, 2022, 37, 2009-2015.	2.6	8
116	Improving Alzheimer's disease outcomes in Down's syndrome. Lancet, The, 2012, 379, 498-500.	13.7	7
117	Best practice in caring for adults with dementia and learning disabilities. Nursing Standard (Royal) Tj ETQq1 10).784314 rg	gBT-/Overlock
118	Differential Associations of Apolipoprotein E $\hat{l}\mu 4$ Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. JAMA Network Open, 2020, 3, e2018221.	5.9	7
119	Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3748.	2.4	7
120	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. Frontiers in Psychiatry, 2021, 12, 701729.	2.6	7
121	Are dedicated research posts of value to psychiatry trainees?. Psychiatric Bulletin, 2004, 28, 260-263.	0.3	7
122	Comparison of Receptive Verbal Abilities Assessed Using the KBIT-2 and BPVS3 in Adults With Down Syndrome. Frontiers in Psychology, 2019, 9, 2730.	2.1	6
123	The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population. Scientific Reports, 2021, 11, 13438.	3.3	6
124	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.8	6
125	Estimation of the minimal clinically important difference on the Aberrant Behaviour Checklist–Irritability (ABC-I) for people with intellectual disabilities who display aggressive challenging behaviour: A triangulated approach. Research in Developmental Disabilities, 2022, 124, 104202.	2.2	6
126	Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis. PLoS ONE, 2017, 12, e0186438.	2.5	5

#	Article	IF	CITATIONS
127	Resource use and cost of annual health checks in primary care for people with intellectual disabilities. Journal of Intellectual Disability Research, 2019, 63, 233-243.	2.0	5
128	Staff training in positive behaviour support for behaviour that challenges in people with intellectual disability: cost-utility analysis of a cluster randomised controlled trial. BJPsych Open, 2020, 6, e15.	0.7	5
129	The COVID-19 pandemic should be last orders for poor care of people with neurodevelopmental disorders. British Journal of Psychiatry, 2021, 218, 302-304.	2.8	5
130	Down's syndrome. Lancet, The, 2003, 362, 80-81.	13.7	4
131	Behavioural phenotypes and mental disorders. Psychiatry (Abingdon, England), 2009, 8, 391-397.	0.2	3
132	A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open, 2019, 9, e033827.	1.9	3
133	About leaving: making sense of moving on. British Journal of Learning Disabilities, 2003, 31, 70-73.	1.1	2
134	Letter to the editor. Journal of Intellectual Disability Research, 2004, 48, 769-770.	2.0	2
135	Insight and other predictors of physical examination refusal in psychotic illness. Journal of Mental Health, 2011, 20, 319-327.	1.9	2
136	Physical Health and Clinical Phenotypes. , 2019, , 71-86.		2
137	Behavioural phenotypes in translation. Journal of Intellectual Disability Research, 2015, 59, 785-786.	2.0	1
138	The Relationship Between Sound–Shape Matching and Cognitive Ability in Adults With Down Syndrome. Multisensory Research, 2017, 30, 537-547.	1,1	1
139	Genetics of Intellectual Disability. , 2019, , 12-27.		1
140	Validity of Criteria for Dementia in Older People With Intellectual Disability. American Journal of Geriatric Psychiatry, 2012, , 1.	1.2	1
141	Behavioral Phenotypes and Genetic Syndromes. Autism and Child Psychopathology Series, 2014, , 109-122.	0.2	1
142	Self-help resources for adults with a learning disability. Psychiatric Bulletin, 2001, 25, 495-496.	0.3	0
143	Mental disorders predicted all cause and cause specific deaths in Finnish adults. Evidence-Based Mental Health, 2002, 5, 93-93.	4.5	0

#	Article	IF	CITATIONS
145	Behavioural and psychological symptoms of dementia in Down syndrome: European development of the novel BPSD-DS evaluation scale. European Neuropsychopharmacology, 2016, 26, S641.	0.7	O
146	New horizons for mental health research in intellectual disabilities. Journal of Intellectual Disability Research, 2017, 61, 519-520.	2.0	0
147	Author's reply to: Difficulties of diagnosing and managing dementia in people with Down syndrome. British Journal of Psychiatry, 2018, 213, 669-669.	2.8	0
148	Author's reply. British Journal of Psychiatry, 2018, 213, 667-668.	2.8	0
149	Reply to "Down Syndrome Cognitive Marker's Significance in Alzheimer's Disease and Dementia Management― Alzheimer's and Dementia, 2019, 15, 1238-1239.	0.8	0
150	Optimising psychotropic medication prescribing to reduce adverse drug events. Journal of Intellectual Disability Research, 2019, 63, 369-371.	2.0	0
151	Cognitive and clinical outcome measures for Alzheimer's disease prevention trials in adults with Down syndrome. Alzheimer's and Dementia, 2020, 16, e043478.	0.8	0
152	Psychiatric issues in aging and dementia. , 2022, , 273-288.		0
153	Mental Health of Older People. , 0, , 149-168.		О